Strategic Developments in 3D Bioprinting Market: What's New? 3D bioprinting largely focuses on the fabrication of anatomical replicas. It offers significant accuracy in the spatial placement of biomaterials, drugs, DNA, proteins, and cells to better guide tissue formation and generation. According to Inkwood Research, the global 3D bioprinting market is expected to project a CAGR of 16.69% during 2023-2032 and garner a revenue of $5693.82 million by 2032. This blog focuses on the new strategic developments in the 3D bioprinting market.
Amgen's Accelerated Drug Testing using a Human Tonsil
Researchers at Amgen British Columbia are using a human tonsil obtained from tonsillectomies to produce a complex cell culture platform to mimic the immune system outside the body. Tonsil tissue encompasses a rich source of immune cells. These include B cells that create antibodies and helper T cells that nudge B cells to make targeted antibodies. Upon being provided the materials to culture the tonsil tissue, the cells formed 3D clusters spontaneously. These behave similarly to that in the body. The researchers plan to use these cultures to test medicines to better understand a drug's ability to elicit an immune response. According to Chadwick King, executive director of Research and site head of Amgen British Columbia, "In this case we are using three-dimensional organoid-like structures that allow us to better replicate human immunity. The long-term goal is to learn from this biology so we can better predict immunity using Artificial Intelligence (AI) and Machine Learning (ML) in the future." (Source) Predicting which protein-based medicines evoke an immune response that can neutralize the molecule remains a big pain point in drug development. Accordingly, the immune tissue platforms may assist in producing new antibodies for development.
BioArm joins Cancer Research
Researchers at the University of Cambridge and King's College London developed BioArm, a lowcost extrusion-based bioprinter. It can be easily transported, folded, and reassembled for printing. It can manufacture complex tumoroids (around 90 seconds per tumoroid) to test potential immunotherapy treatments. Tumoroids are 3D cell cultures that mimic tumor tissues. Immunotherapy uses the immune system to identify and fight cancer cells. There have been increased efforts to mimic the tumor microenvironment with regard to in vitro cancer models for therapeutic testing. Also, modeling a tumor in vitro can help minimize the animal model used for treatment methods in cancer research. In this regard, 3D bioprinting is an efficient tool to help construct in vitro cancer models. However, the existing bioprinters are difficult to maneuver or reassemble. In comparison, BioArm is portable and can be assembled and disassembled within 15 minutes. Corrado Mazzaglia, Research Associate in the Biointerface Research Group, says, "Bioprinted cancer models mimic the 3D heterogeneity of real tumors. BioArm has the potential to screen a wide range of tumor therapies and could play a crucial role in the future development of cancer drug testing approaches." (Source)